Insulin Pump Market to Reach USD 18.93 Billion by 2035 as Closed-Loop Systems, Patch Pumps and Pharmacy Access Reshape Diabetes Care
News originally published by
GlobeNewswireThe global insulin pump market was valued at USD 7.53 billion in 2025, is estimated at USD 8.26 billion in 2026 and is projected to reach USD 18.93 billion by 2035, a CAGR of 9.65%. Type 1 diabetes accounted for 60% of 2025 demand, and an estimated 350,000 to 515,000 people in the U.S. are on pump therapy.
Ottawa, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insulin pumps have moved from a niche therapy for type 1 diabetes into a software-led category. Towards Healthcare estimates the insulin pumps market at USD 8.26 billion in 2026, rising to USD 18.93 billion by 2035, an absolute gain of USD 10.67 billion. The pump is now the hardware anchor of a recurring-revenue ecosystem: MiniMed reported that about 82% of its fiscal 2026 revenue came from sensors, consumables, software and services rather than pumps, a study published by Towards Healthcare, sister firm of Precedence Research.

2026 shows how fast the category is changing. MiniMed listed on Nasdaq in March and completed its separation from Medtronic on October 15. The FDA cleared the MiniMed Flex pump in March and the Beta Bionics Mint patch pump in September. Insulet reported USD 842.0 million of third-quarter revenue on November 4. A CMS rule effective January 1, 2026 moves insulin pumps and continuous glucose monitoring devices to monthly rental payment.
Decision-makers now face practical questions: which platforms win the shift from multiple daily injections, how quickly type 2 diabetes becomes a core segment, whether pharmacy channels can replace durable-medical-equipment billing, and how reimbursement reform will change margins.
Full report: https://www.towardshealthcare.com/insights/insulin-pumps-market
Request a sample: https://www.towardshealthcare.com/download-sample/5025
Market Size and Growth
Table 1: Insulin Pump Market Snapshot
| Market Indicator | Value | |
| Market size, 2025 (base year) | USD 7.53 billion | |
| Market size, 2026 | USD 8.26 billion | |
| Forecast market size, 2035 | USD 18.93 billion | |
| CAGR, 2026 to 2035 | 9.65 | % |
| Absolute growth, 2026 to 2035 (calculated) | USD 10.67 billion | |
| Growth multiple, 2026 to 2035 (calculated) | About 2.3x | |
| Historical data period | 2020 to 2023 | |
| Leading region, 2025 | North America | |
| Largest type and disease segments, 2025 | Tethered pumps (55%); Type 1 diabetes (60%) | |
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher

Figure 1: Insulin pump market snapshot, 2025 to 2035
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Growth rests on a larger diabetes population (643 million people projected by 2030 and 783 million by 2045), automated insulin delivery that pairs pumps with sensors and phones, wider tubeless and patch designs, and pharmacy channels that lower the barrier to starting therapy.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Segment Intelligence: Dominant and Fastest-Growing Segments
Table 2: Leading and Fastest-Growing Segments, 2025
| Segment Group | Leading | Fastest-Growing | Why It Matters |
| By Type | Tethered pumps (55%) | Patch pumps | Patch designs remove tubing; tethered pumps keep the cost edge |
| By Product | MiniMed (40%) | Tandem | Algorithm quality and sensor integration decide product share |
| By Accessories | Insulin set insertion devices (40%) | Reservoirs and cartridges | Consumables create repeat revenue |
| By Disease Indication | Type 1 diabetes (60%) | Type 2 diabetes (40%) | Type 2 is the largest untapped pool |
| By End-Use | Hospitals (50%) | Homecare (30%) | Care is moving to the home |
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher

Figure 2: Segment shares and modeled values, 2025 (USD 7.53 billion base)
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
By type. Tethered pumps held 55% of 2025 demand (about USD 4.14 billion modeled) on display screens and lower cost. Patch pumps, at 45% (about USD 3.39 billion modeled), are the fastest-growing type because they remove tubing.
By product. MiniMed led with 40% (about USD 3.01 billion modeled), helped by an algorithm that corrects glucose every five minutes. Tandem, at 25% (about USD 1.88 billion), is the fastest-growing line; the remaining 35% (about USD 2.64 billion) spans Accu-Chek, Omnipod and others.
By accessories. Set insertion devices led with 40% (USD 3.01 billion modeled), ahead of reservoirs and cartridges at 35% and batteries at 25%. Reservoirs and cartridges are the fastest-growing accessory as lighter designs reduce insulin wastage.
By disease indication. Type 1 diabetes accounted for 60% (USD 4.52 billion modeled). Type 2 diabetes, at 40% (USD 3.01 billion), is the growth area: Insulet said type 2 made up over 40% of its U.S. new starts in the third quarter of 2026.
By end-use. Hospitals held 50% (about USD 3.77 billion modeled) thanks to trained staff and advanced devices. Homecare, at 30% (about USD 2.26 billion), is the fastest-growing setting.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Regional and Country Analysis
Table 3: Regional Positioning
| Region | Market Position | Main Demand Signals |
| North America | Largest region, 2025 | Reimbursement coverage, 350,000 to 515,000 U.S. pump users |
| Europe | Sizable share expected through 2035 | Aging population, EU diabetes policy |
| Asia Pacific | Notable region | High prevalence in India and China |
| Latin America | Growing region | Rising diabetes burden, led by Brazil |
| Middle East and Africa | Growing region | Covered in the report |
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
North America and the United States. The region leads on established manufacturers, supportive FDA pathways and favorable reimbursement. CMS finalized rules in December 2025 that treat insulin pumps and continuous glucose monitors as serviced items paid by monthly rental from January 1, 2026, and the first national remote-delivery bidding round starts January 1, 2028. Tandem now routes 15% of U.S. sales through pharmacies, and Beta Bionics expects 37% to 39% of new starts to be reimbursed through the pharmacy benefit.
Europe. Europe carries the highest type 1 diabetes burden globally, and the EU has set a 2030 blueprint for diabetes care. MiniMed's international net sales rose 18.1% to USD 603 million in the quarter ended July 31, 2026, and Insulet's international Omnipod revenue rose 31.7% to USD 266.2 million in the third quarter. Roche, by contrast, is phasing out Accu-Chek pump consumables in the UK and Ireland by the end of January 2026.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
What Is Changing in the Industry
1. MiniMed Becomes a Stand-Alone Diabetes Company
MiniMed began trading on Nasdaq in March 2026, and on October 15 Medtronic completed the split-off through an exchange offer that was 5.4 times subscribed. MiniMed ended fiscal 2026 with about 659,000 pump users and USD 3.102 billion in revenue.
What it indicates: diabetes technology now attracts dedicated capital, and full-stack platform competition will intensify.
2. Incumbents Race to Patch Pumps and Fully Closed Loop
MiniMed Flex won FDA clearance in March 2026 and reached Medicare beneficiaries after launch. On September 1, MiniMed said it had submitted the Fit patch pump to the FDA and completed enrollment in the pivotal trial of its Vivera fully closed-loop algorithm. U.S. new pumps sold rose over 20% year on year.
What it indicates: the next cycle is about removing meal announcements and tubing.
3. Beta Bionics Enters the Patch Segment
Beta Bionics received FDA clearance for Mint in September 2026 and plans a U.S. launch in the first quarter of 2027, with capacity for at least 1.5 million units in 2027. Insulet told investors it expects slower 2027 growth as it prepares Omnipod 6 and meets new competitors.
What it indicates: the patch segment, long led by one brand, is becoming a contested market.
4. Pharmacy and Rental Models Replace Traditional DME Billing
Beta Bionics' pharmacy-benefit sales rose 118% to USD 13.6 million in the third quarter of 2026, and 15% of Tandem's U.S. sales now run through pharmacies. CMS cited software change and cybersecurity needs when it moved pumps to a rental model.
What it indicates: access, not only device performance, will decide who wins new starts.
5. Sensor Choice and Type 2 Expansion Widen the Addressable Base
The MiniMed 780G now works with the Abbott-made Instinct sensor, which the company says opens it to more than 4.5 million Abbott sensor users. Tandem has extended t:slim X2 compatibility with Abbott's FreeStyle Libre 3 Plus to 11 international markets.
What it indicates: interoperability is lowering switching barriers.

Figure 3: Key 2026 developments in insulin pump technology and corporate structure
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Key Market Drivers
- Expanding diabetes population: 783 million people projected by 2045.
- Sensor and pump integration: MiniMed's CGM attachment rate reached 69% in the quarter ended July 31, 2026.
- Smartphone control and patch designs appeal to first-time pump users.
- Reimbursement coverage: MiniMed Flex now covers Medicare and Medicare Advantage beneficiaries.
- Conversion from injections: over 85% of Omnipod new customers and 69% of Beta Bionics new starts came from daily injections.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Major Challenges
- Reimbursement reform: national bidding starts in 2028, after CMS drew more than 900,000 comments on the proposal.
- Slower growth at the leader: Insulet expects growth to moderate in 2027.
- Profitability pressure: MiniMed's net loss was about 10% of fiscal 2026 revenue.
- Product transition risk: Beta Bionics flagged up to USD 8.5 million of fourth-quarter revenue deferral ahead of the Mint launch.
- Hospital and safety limits: critical illness and ketoacidosis restrict inpatient pump use.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Emerging Opportunities
- Type 2 diabetes expansion. Beta Bionics targets a type 2 label around mid-2027, and type 2 already exceeds 40% of Insulet's U.S. new starts.
- Fully closed-loop algorithms. Tandem targets a 2028 launch; MiniMed expects Vivera in the second half of 2027.
- Patch pump portfolios. MiniMed Fit and Beta Bionics Mint target the fastest-growing type.
- Pharmacy-channel scale. Lower upfront cost and simpler access.
-
Direct international models. Tandem Mobi is available in 12 countries; Insulet's international revenue grew 31.7%.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Company and Competitive Intelligence
The report names Medtronic, Insulet, Medzer, MicroPort Scientific, EOFlow, Debiotech, Lenomed Medical, Microtech Medical, Cequr, Roche, Ypsomed, Zealand Pharma, Terumo and Vicentra among leading participants. By product, MiniMed holds 40% and Tandem 25%. Economics differ: Insulet is highly profitable, Tandem is near break-even, and MiniMed and Beta Bionics are still investing.
Table 4: Key Companies and Latest Reported Data
| Company | Role or Key Products | Latest Reported Data | Strategic Direction |
| MiniMed | MiniMed 780G, Flex and Go; Simplera and Instinct sensors | FY26 net sales USD 3.102 billion; Q1 FY27 net sales USD 843 million, up 16.6% | U.S. Flex rollout, Fit patch pump under FDA review, Vivera closed loop for 2H 2027 |
| Insulet | Omnipod 5 tubeless system | Q3 2026 revenue USD 842.0 million, up 19.2%; operating margin 22.5% | Type 2 action plan, Omnipod 6 preparation, USD 1 billion buyback authorization |
| Tandem Diabetes Care | t:slim X2 and Tandem Mobi with Control-IQ+ | Q3 2026 sales USD 283.7 million; about 33,000 pumps shipped; gross margin 57% | Pharmacy model, international direct sales, planned CEO transition, closed-loop study |
| Beta Bionics | iLet bionic pancreas; Mint patch pump | Q3 2026 net sales USD 35.5 million, up 30%; 2026 revenue guidance USD 124 to 126 million | Mint launch in 1Q 2027, type 2 label expansion, Eversense 365 integration |
| Roche | Accu-Chek pumps; SmartGuide CGM | Pump consumables phased out in the UK and Ireland by end of January 2026 | Focus shifting toward sensors and digital tools |
| Ypsomed | Former mylife YpsoPump maker; injection systems | FY 2025/26 revenue CHF 731.0 million; Delivery Systems up 20% | Sold its diabetes care unit; now a pure-play injection-device specialist |
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher

Figure 4: Latest reported results of leading insulin pump companies
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Customer and Buyer Intelligence
Table 5: Buyer Groups and Commercial Signals
| Target Account Group | Decision-Makers | Purchase Signals | Commercial Opportunity |
| Hospitals and diabetes centers | Endocrinologists, diabetes educators, clinical informatics leads | Hospitals hold 50% of demand; trained staff are required for safe pump use | Training programs, inpatient-ready protocols, data connectivity |
| Type 2 and primary care clinics | Primary care physicians, endocrinologists | Type 2 above 40% of Insulet U.S. starts; most new starts come from injections | Sampling programs, clinician education, retention support |
| Medicare and commercial payers | Medical directors, coverage and pricing teams | CMS monthly rental rule; bidding round from 2028 | Outcome-based contracts built on time-in-range data |
| Pharmacy benefit managers and pharmacies | Formulary committees, specialty pharmacy leads | Tandem formulary reach near 50% of U.S. lives; pharmacy gains at Beta Bionics | Pharmacy-channel supply agreements |
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
How Towards Healthcare Supports Decision-Making
Master Dataset. Historical (2020 to 2023) and forecast (2025 to 2035) values by type, product, accessories, disease indication, end-use and region, supporting revenue models and pricing decisions.
Towards Healthcare Quadrant. Positions pump makers, sensor partners and entrants on innovation and commercial strength, helping business development teams screen partners and targets.
Interactive Intelligence Dashboard. One view of market size, segments, regions and company activity, so executives can track results, approvals and reimbursement changes before each board review.
Quality & Manufacturing Intelligence. Analysis of infusion-set reliability, cartridge and battery performance, cybersecurity validation and capacity, supporting sourcing and plant-investment decisions.
Customized Research. Tailored studies, such as type 2 pump users in Europe or pharmacy-channel pump revenue in the U.S., supporting market-entry, pricing and tender decisions.
Table 6: Solutions Overview
| Solution | What It Provides | How It Helps |
| Master Dataset | Segment and regional values, 2020 to 2035 | Revenue modeling and portfolio planning |
| Towards Healthcare Quadrant | Competitive positioning of pump and sensor companies | Partner and target screening |
| Interactive Intelligence Dashboard | Filterable market, segment and company views | Faster board and investment reviews |
| Quality & Manufacturing Intelligence | Component, reliability and capacity analysis | Sourcing and capacity decisions |
| Customized Research | Tailored country, channel or product studies | Market-entry, pricing and tender decisions |
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Why Continuously Updated Intelligence Matters
Pump markets move on a monthly, quarterly, six-monthly and annual rhythm. Monthly updates capture clearances such as Mint in September 2026. Quarterly updates follow earnings: Beta Bionics on October 27, Insulet on November 4 and Tandem on November 5 each shifted the view on starts and launch timing within nine days. Six-monthly reviews suit pipeline checks, such as closed-loop programs due in 2027 and 2028. Annual updates re-base forecasts ahead of national bidding in 2028.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Strategic Outlook
- CEOs and CXOs: Treat the pump as a platform. Recurring sensors, consumables and services made up about 82% of MiniMed's fiscal 2026 revenue.
- Strategy and Business Development: Patch pumps and type 2 are the contested ground; two new patch entrants arrive in 2026 and 2027, so partnership windows are narrow.
- R&D: Fully closed-loop algorithms are reaching pivotal stage at three companies, and programs that still need meal announcements risk looking dated.
- Procurement: CMS treats pumps as serviced rental items, so health systems should model bundled monthly pricing before the 2028 bidding round.
- Investors: Growth leaders are diverging on profitability: Insulet's adjusted operating margin reached 22.0% in Q3 2026, while MiniMed guides to about 16% adjusted EBITDA margin for fiscal 2027.
- Manufacturers and Suppliers: Capacity and interoperability decide the winners; Beta Bionics plans at least 1.5 million disposable units in 2027.
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Company Ecosystem

Figure 5: Insulin pump market company ecosystem, supply side and demand side
Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher
Call to Action
The insulin pump market is set to more than double by 2035. The full report provides segment models, regional detail and company analysis for planning.
- Report: https://www.towardshealthcare.com/insights/insulin-pumps-market
- Request a sample: https://www.towardshealthcare.com/download-sample/5025
-
Buy this report: https://www.towardshealthcare.com/checkout/5025
Fill out the form for relevant samples, case studies, and examples. sales@towardshealthcare.com
Related Reports
- Insulin Delivery System Market: https://www.towardshealthcare.com/insights/insulin-delivery-system-market-sizing
- Insulin Drugs and Delivery Devices Market: https://www.towardshealthcare.com/insights/insulin-drugs-and-delivery-devices-market-sizing
- Diabetes Care Devices Market: https://www.towardshealthcare.com/insights/diabetes-care-devices-market-sizing
- Continuous Glucose Monitoring Devices Market: https://www.towardshealthcare.com/insights/continuous-glucose-monitoring-devices-market-sizing
- Global Insulin Market: https://www.towardshealthcare.com/insights/global-insulin-market-size
- AI in Healthcare Market: https://www.towardshealthcare.com/insights/ai-in-healthcare-market
- Cardiometabolic Diseases Market: https://www.towardshealthcare.com/insights/cardiometabolic-diseases-market-sizing
- U.S. Patient Monitoring Devices Market: https://www.towardshealthcare.com/insights/us-patient-monitoring-devices-market-sizing
- Blood Pressure Measuring Devices Market: https://www.towardshealthcare.com/insights/blood-pressure-measuring-devices-market
- Cardiovascular Devices Market: https://www.towardshealthcare.com/insights/cardiovascular-devices-market-sizing
- Rehabilitation Equipment Market: https://www.towardshealthcare.com/insights/rehabilitation-equipment-market-sizing
- Anesthesia Monitoring Devices Market: https://www.towardshealthcare.com/insights/anesthesia-monitoring-devices-market
- Hospital Services Market: https://www.towardshealthcare.com/insights/hospital-services-market
- Nebulizer Devices Market: https://www.towardshealthcare.com/insights/nebulizer-devices-market-sizing
- AI in Life Sciences Market: https://www.towardshealthcare.com/insights/ai-in-life-sciences-market
- Medical Device Testing Market: https://www.towardshealthcare.com/insights/medical-device-testing-market-sizing
- Smart Implant in Orthopedics Market: https://www.towardshealthcare.com/insights/smart-implant-in-orthopedics-market-sizing
- Medical Videoscope Market: https://www.towardshealthcare.com/insights/medical-videoscope-market-sizing
- Arthroscopy Devices Market: https://www.towardshealthcare.com/insights/arthroscopy-devices-market-sizing
- U.S. Behavioral Health Market: https://www.towardshealthcare.com/insights/us-behavioral-health-market
About Towards Healthcare
Towards Healthcare is a healthcare market research and consulting firm that publishes market intelligence across medical devices, diagnostics, biotechnology, pharmaceuticals, healthcare services, healthcare IT, life sciences and cell and gene therapies. Its reports combine expert interviews, secondary research and proprietary databases to help executives, investors and suppliers size markets, track competitors and plan investments.
Our Partners
Precedence Research: https://www.precedenceresearch.com/
Towards Packaging: https://www.towardspackaging.com/
Towards Chemical & Materials: https://www.towardschemandmaterials.com/
Connect With Us
USA: +1 804 441 9344 | APAC: +61 485 981 310 or +91 87933 22019
Singapore: +65 3105 1271 | Europe: +44 7383 092 044
Email: sales@towardshealthcare.com
Social Media
LinkedIn: https://www.linkedin.com/company/towards-healthcare-research-and-consulting
X: https://x.com/TowardsHealths
Medium: https://medium.com/@TowardsHealthcare
Instagram: https://www.instagram.com/towards_healthcare
YouTube: https://www.youtube.com/@TowardsHealthcare
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
